

## Rhythm Biosciences Granted China Patent

- **Divisional patent has been granted in China**
- **Granted patent will provide IP protection in China until 2031**
- **Patents already granted in Australia, Europe and Japan**

**4 November 2019, Melbourne:** Rhythm Biosciences (ASX: RHY), a medical diagnostics company with its lead product, ColoSTAT<sup>®</sup>, a global, low cost, simple blood test for the accurate and early detection of colorectal cancer, has received notice that its divisional patent for ColoSTAT<sup>®</sup> has been granted in China.

Previously, Rhythm has been granted patents for the diagnosis of colorectal cancer in Australia, China, Europe and Japan, and has patent applications pending in the US, Brazil and India.

Granting of the divisional patent expands the combinations of biomarkers that can be used in the ColoSTAT<sup>®</sup> test kit marketed in China beyond those covered by the original granted Chinese patent. Together these patents cover Rhythm's preferred sets of biomarker combinations and will provide protection reaching out until 2031.

Glenn Gilbert, CEO of Rhythm Biosciences said, "filing patent protection is a very important basis in commercialising the technology of Rhythm. It gives us a strong hold on our unique IP and is important in driving shareholder value. We will continue to seek to expand on our existing IP protection in the future."

"With the world's largest and ageing population, China represents a large potential market for ColoSTAT<sup>®</sup>. Over the coming years, colorectal cancer cases across the western 15 provinces in China are expected to increase by 64% to over 642,000 cases per year, with deaths from colorectal cancer increasing by over 30% to over 221,000. As a reference, Australia has circa 16,000 colorectal cancer cases and over 5,000 deaths per year".

"Furthermore, the faecal based testing as part of China's bowel screening program currently only reaches circa 13% of the 40-74 year old population with a compliance rate of 19%, versus a compliance rate of 41% in Australia."

"ColoSTAT<sup>®</sup> has the potential to be a global, low cost and accurate diagnostic tool that would increase screening and compliance across all population ages, not limited to the typical 50-74 year old screening age. We remain confident that ColoSTAT<sup>®</sup> will have a significant impact both socially and economically around the world," Mr Gilbert said.

---

**Rhythm Biosciences**

ACN: 619 459 335  
ASX: RHY

**Issued Capital**

100,750,000 Shares  
3,504,200 Options and  
Performance Shares

**Australian Registered Office**

Level 17, 500 Collins Street  
Melbourne VIC 3000  
[www.rhythmbio.com](http://www.rhythmbio.com)

**Directors**

Otto Buttula – Chairman of the Board  
Trevor John Lockett – Executive Director  
Louis James Panaccio – Non-Executive Director  
David John White – Non-Executive Director

For further information, please contact:

Glenn Gilbert  
Chief Executive Officer  
+61 3 8256 2880

Rudi Michelson  
Monsoon Communications  
+61 3 9620 3333

### **About Rhythm Biosciences**

ASX-listed Rhythm Biosciences is developing and commercialising a screening and diagnostic tool for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT<sup>®</sup>, is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower cost. ColoSTAT<sup>®</sup> also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT<sup>®</sup> is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure.

ColoSTAT<sup>®</sup> has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer. Globally, over 850,000 people die from colorectal cancer each year.